IQVIA SOLUTIONS ASIA PTE. LTD.
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Computer Processing and Data Preparation and Processing Services, Information Retrieval Services), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about IQVIA SOLUTIONS ASIA PTE. LTD.
Live alerts from global media, monitored by Business Radar
2025-04-01 (shinailbo.co.kr)
Yuhan Corporation 'La La Ola', Arginine General Pharmaceutical Market No. 1
Yuhan Corp. announced on the 1st that La La Ola, a high content L-arginine product, has achieved the No. 1 sales in the domestic drug arginine market.In accordance with the data on the drug statistics company IQVIA data, 'La La Ola' achieved sales of about 2.9 billion won in 2023 to about 4.5 billion won in 2024, and about 55%of 2024. It grew up, and Yuhan Corp. selected Shin Dong -yeop as an advertising model in May 2024 to strengthen its marketing. Since then, various public relations activities such as TV commercials and campaigns have been enhanced to increase consumer awareness. As a result, the leading position in the arginine market
Read more
2025-03-26 (drugstorenews.com)
Hikma launches cisatracurium besylate, gets OK for Kloxxado in Canada |
Cisatracurium besylate injection has a market value of approximately $14 million in the 12 months ending January 2025, per IQVIA.
Read more
2025-03-19 (globenewswire.com)
ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets
PRINCETON, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of...
Read more
2025-03-10 (owler.com)
Reports - Endo: Endo launches doxycycline for injection
Doxycycline for injection 100 mg vial had a market value of approximately $49 million for the 12 months ended Sept. 30, 2024, per IQVIA.
Read more
2025-03-10 (businessupturn.com)
Lupin share price surges over 1.50% after US launch of Rivaroxaban, brokerages bullish |
Shares of Lupin Ltd. (NSE: LUPIN) surged 1.57% to ₹2,061.80 in early trade today following the company's US launch of generic Rivaroxaban 2.5mg tablets (gXarelto). The stock opened at ₹2,049.80, hit an intraday high of ₹2,080.10, and is currently trading above its previous close of ₹2,030.00. The move comes after Lupin announced the launch of […]
Read more
2025-03-04 (intelligenthq.com)
Overcoming Pharmaceutical Launch Challenges: Insights from Oxford University Press
Oxford University Press helps pharmaceutical companies overcome product launch failures by providing trusted, data-driven content strategies.
Read more
2025-03-04 (kyodo.co.jp)
Japan Medical Pharmaceutical Market, both in the fourth quarter and in the 2024 period, the highest amount since the 2005 IQVIA release | Prescribing | Kyodo Tsushin Co., Ltd.
Kyodo Tsushin Co., Ltd. is a group media company that creates new brand values through its editorial capabilities and network work, which have been cultivated as a group company of Japan's leading telecommunications company. We provide reliable business information and NEWS from all over the country, helping people and organizations succeed.
Read more
2025-02-26 (openpr.com)
Healthcare Consulting Services Market to Set an Explosive Growth in Near Future | Bain & Company, Inc., IQVIA, Inc., Boston Consulting Group
Press release - Coherent Market Insights - Healthcare Consulting Services Market to Set an Explosive Growth in Near Future | Bain & Company, Inc., IQVIA, Inc., Boston Consulting Group - published on openPR.com
Read more
2025-02-06 (freepressjournal.in)
Maharashtra Government Appoints IQVIA To Develop Centre Of Excellence And Conduct Feasibility Study
The initial resolution specified the annual expenditure for the project as ₹20.79 crore, without clarifying that the amount was exclusive of taxes.
Read more
2025-01-30 (drugstorenews.com)
Glenmark launches generic vitamin K1 injectable emulsion |
Vitamin K1 injectable emulsion had a market value of approximately $19.7 million, for the 12 months ending November 2024, per IQVIA.
Read more
2025-01-22 (biospace.com)
IQVIA to Announce Fourth-Quarter and Full-Year 2024 Results on February 6, 2025 -
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its fourth-quarter and full-year 2024 financial results before the market opens on Thursday, February 6, 2025. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com.
Read more
2025-01-20 (rifday.it)
Iqvia, revenues from online pharmacies and parapharmacies will exceed one billion for the first time in 2024 -
Rome, 21 January - This could have been foreseen since last June, when Iqvia released the data relating to the performance of the online medicines market in the first five months of 2024, reporting a double-digit growth trend, with an increase around more than 20% in values and more than 16% in […]
Read more